> Exhibit 99.1



|For immediate release: | Media Contacts:   
|---------------------- | ------------------
|April 7, 2009          | Ray Kerins        
|                       | (212) 733-9203    
|                       | Joan Campion      
|                       | (212)733-2798     
|                       | Investor Contacts:
|                       | Suzanne Harnett   
|                       | (212) 733-8009    
|                       | Jennifer Davis    
|                       | (212) 733-0717    

> Pfizer Announces Operating Structure and Select Senior
>       Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition
>       ---
>       Innovative Approach to Research Supporting Nine Diverse Businesses:
>       Primary Care, Specialty Care & Vaccines, Emerging Markets, Oncology,
>       Established Products, Animal Health, Capsugel, Consumer Health, Nutritional
>       Health
>     NEW YORK, NY, April 7 -- Pfizer (NYSE: PFE) today announced the planned
>       leadership and organizational structure for its research and commercial
>       operations that will become effective when the Wyeth acquisition closes.
>     The company will establish a unique research model designed
>       to advance the strong scientific capabilities of both Pfizer and Wyeth (NYSE:
>       WYE) and to support the new company's nine diverse health care businesses.
>       At the senior-most level of the organization, Pfizer will retain eight senior
>       executives from Wyeth who will join the company post-closing.
>     CEOs Jeff Kindler and Bernard Poussot and senior leadership
>       of both companies continue to work closely together through the integration
>       process. As planning continues, additional appointments are expected that
>       will enable Pfizer to begin appreciating the benefits of the combined company
>       with a new team and structure in place immediately following the close of
>       the acquisition.
>     A New Approach for Research
>       To maximize new opportunities in biopharmaceutical research, Pfizer will
>       form two distinct research organizations. The PharmaTherapeutics Research
>       Group will focus on the discovery of small molecules and related modalities
>       and will be led by Martin Mackay, who now leads Pfizer Global Research &
>       Development (PGRD). The BioTherapeutics Research Group will focus on large-molecule
>       research, including vaccines, and will be led by Mikael Dolsten, who currently
>       serves as President of Wyeth Research. Both Dr. Dolsten and Dr. Mackay will
>       serve as presidents of their respective organizations and members of Pfizer's
>       Executive Leadership Team, and both will report to Pfizer Chairman and Chief
>       Executive Officer Jeff Kindler. 
>       The new BioTherapeutics Research Group will capitalize on Wyeth's industry-leading
>       expertise in biologics and build on the momentum established by both Pfizer's
>       Biotherapeutics and Bioinnovation Center (BBC) and centers of large-molecule
>       research and pharmaceutical science excellence in PGRD, which will be part
>       of the new, larger group. This new group's mandate will be to create a broad
>       and deep pipeline in vaccines, antibodies, proteins, peptides, nucleic acids
>       and other novel modalities. The PharmaTherapeutics Research Group will continue
>       to advance the strong legacy of both Pfizer and Wyeth in small-molecule
>       discovery.
>     Within these two research groups, small, focused scientific
>       teams - targeting specific high-potential therapeutic areas and leading-edge
>       innovative technologies - will be led by world-class Chief Scientific Officers
>       who will act as single points of accountability for delivering medical advances
>       on behalf of the company. These teams will be responsible for creating a
>       rich portfolio of both small and large molecules from across both research
>       organizations and, in particular, with delivering positive proofs-of-concept
>       for Pfizer's business units to develop. They will also aggressively pursue
>       collaborations with top academic, public-sector and private-sector institutions
>       to accelerate research and development of new medicines. 
>       The combined scientific teams and programs of the two companies will enable
>       Pfizer to make significant advances in vaccines and neuroscience, among
>       many other areas of unmet medical need. In that connection, Emilio Emini,
>       who currently heads Wyeth's Vaccine Research; and Development, will join
>       Pfizer as Chief Scientific Officer, Vaccine Research, and Menelas Pangalos,
>       who currently serves as Wyeth's Head of Discovery, will join Pfizer as Chief
>       Scientific Officer, Neuroscience Research. Dr. Emini and Dr. Pangalos bring
>       incomparable scientific expertise and outstanding leadership to Pfizer,
>       which are essential to building the world's premier biopharmaceutical research
>       and development organization.
>     Additionally, Pfizer will form a team of top scientists from
>       both companies who will seek and evaluate new technologies, platforms and
>       pre-proof-of-concept small and large molecules from external sources. As
>       this group identifies promising early-stage candidates from outside the
>       company, it will collaborate with Pfizer's business development team to
>       pursue these opportunities. By complementing Pfizer's internal research
>       efforts, these scientists will help assure Pfizer has access to the broadest
>       set of early stage compounds and technologies available to find new medicines
>       for patients.
>     "Creating two distinct, but complementary, research organizations,
>       led by the top scientist from each company, will provide sharper focus,
>       less bureaucracy and clearer accountability in drug discovery," Mr.
>       Kindler said. "This structure powerfully states our commitment to becoming
>       the industry leader in small molecules, large molecules and vaccines. Our
>       approach to research will fuel our discovery efforts, inspire top talent
>       and translate into high-impact new medicines for patients. I am honored
>       that world-class scientists like Drs. Dolsten, Emini and Pangalos will be
>       joining the outstanding scientists at Pfizer and, as we continue our integration
>       planning, I look forward to our welcoming many more distinguished Wyeth
>       scientists to our organization."
>     Enhanced Commercial Operating Structure
>       The new Pfizer will consist of nine diverse global health care businesses.
>       As is the case at Pfizer today, the leader of each of the company's biopharmaceutical
>       businesses will have clear accountability for results from initial product
>       development to providing access to patients and through to the end of the
>       product's life cycle. The businesses will be led by world-class executives
>       from both Pfizer and Wyeth who will have the resources to pursue attractive
>       growth opportunities and to meet the needs of patients and customers around
>       the world.
>     Ian Read, currently President of Worldwide Pharmaceutical Operations for
>       Pfizer, will become Group President, Pfizer BioPharmaceutical Businesses,
>       and remain a member of the Executive Leadership Team reporting to Mr. Kindler.
>       In that capacity, he will lead a group that includes five leading biopharmaceutical
>       businesses:
>     Primary Care, led by President Olivier Brandicourt, will be the world's
>         leading primary care business, with strong positions in cardiovascular
>         (#1), infectious disease (#2), immunology (#4) and central nervous system
>         diseases (#2), and with unique research and development opportunities
>         in areas like Alzheimer's disease and pain.
>       Specialty Care and Vaccines will be led by President Geno Germano, currently
>         President of Wyeth's U.S. and Pharmaceuticals business units. It will
>         be the world's second largest specialty care business, with prominent
>         positions in inflammation (#2), vaccines (#4) and immunology (#4); leading
>         products such as Enbrel, the world's leading biologic and Prevnar, the
>         world's leading vaccine; and a strong pipeline of small- and large-molecule
>         compounds.Jim Connolly, currently Wyeth's Executive Vice President & General
>       Manager, Vaccines, will join the Specialty Care and Vaccines Business Unit
>       as President, Vaccines, reporting to Mr. Germano. He will lead an integrated
>       vaccine business comprising marketing, sales and medical affairs, which
>       will align closely with the Vaccine Research group led by Dr. Emini. They
>       will work together to bring innovative new vaccines to patients around the
>       globe.
>     Emerging Markets will continue to be led by President Jean-Michel Halfon
>         and will have a significantly enhanced presence in high-growth, less-developed
>         and under-penetrated markets, including those in Latin America, the Middle
>         East and China.
>       Oncology will continue to be led by President Garry Nicholson and will
>         continue to bring patients important treatments like Sutent. It will also
>         bring to market one of the most robust oncology product pipelines in the
>         biopharmaceutical industry, one that includes compounds focusing on diverse
>         tumor types including lung, colorectal, liver, prostate and breast.
>       Established Products will continue to be led by President David Simmons
>         and will continue to be a strong global business in a marketplace that
>         is expected to see significant growth in the years ahead. Through portfolio
>         enhancement and expansion activities, including new partnerships, Established
>         Products will continue to extend Pfizer's reach into this important market
>         segment.Cavan Redmond, currently President of Wyeth's Consumer Healthcare business,
>       will become Group President, Pfizer Diversified Businesses, join Pfizer's
>       Executive Leadership Team and report to Mr. Kindler. This group will include
>       four unique businesses, each meeting important customer needs and offering
>       significant growth:
>     Animal Health will continue to be led by President Juan-Ramón
>         Alaix and will have an enhanced leading position in the industry, with
>         important large animal and companion animal products and a platform that
>         includes vaccines, parasiticides and anti-infectives.
>       Capsugel will continue to be led by President Guido Driesen and will
>         continue to be the world's pre-eminent manufacturer and developer of capsule
>         products, equipment and services for the pharmaceutical and associated
>         health care industries.
>       Consumer Health will be led by President Paul Sturman, currently President,
>         US and Global Business Development, New Products for Wyeth Consumer Healthcare.
>         Consumer Health will remain a leader in analgesics, cough/cold/allergy
>         and vitamin/nutritional supplements, including brands such as Advil®,
>         Caltrate®, Centrum®, ChapStick®, Robitussin® and ThermaCare®.
>       Nutritional Health will be led by President Erica Mann, currently Managing
>         Director of Wyeth Australia and New Zealand. The Nutritional business
>         at Wyeth operates in more than 50 countries and has a portfolio that includes
>         a full line of nutritional products, including infant formulas, follow-on
>         formulas, growing-up milks, and prenatal and adult supplements.Mr. Kindler stated: "By putting together these businesses and combining
>       in one team a number of strong and experienced Pfizer and Wyeth leaders,
>       we are creating the world's premier biopharmaceutical company - one that
>       is powerfully positioned to provide substantial value for patients, customers,
>       colleagues and shareholders."
>     Integration Progress
>       Added Chief Financial Officer Frank D'Amelio, who is leading the integration
>       on behalf of Pfizer: "With today's announcement we have taken another
>       significant step in preparing for the combining of these two great companies.
>       Having our organizational structure in place is critical to the combined
>       company being operational on Day One, and the appointment of these leaders
>       will accelerate our ability to do so.
>     "We have made substantial progress in a short period of time, particularly
>       in financing, as well as other requirements for closing. Our progress affirms
>       how well these two companies fit together, the value of this combination,
>       and the commitment of our companies to rapid and successful integration,"
>       Mr. D'Amelio said.
>     Mr. Kindler noted: "I want particularly to thank Wyeth Chief Executive
>       Officer Bernard Poussot for his strong and steady leadership and his partnership.
>       He is an instrumental part of our integration efforts and will continue
>       to provide us with critical counsel and support until the close of the acquisition.
>       Bernard's commitment to Wyeth leaders and to the success of the combined
>       company is extraordinary.
>     "We look forward to welcoming these new colleagues and I am confident
>       Pfizer will be strengthened by the addition of many other exceptional Wyeth
>       scientists and business leaders. They will join Pfizer colleagues with whom
>       they share a commitment to delivering the full potential of the Pfizer-Wyeth
>       combination to patients, customers and investors," Mr. Kindler concluded.
>     The leadership team will begin working together immediately upon the completion
>       of the acquisition. Until the acquisition is complete, Pfizer and Wyeth
>       leadership will continue in their current roles. Pfizer announced on January
>       26, 2009, that it is acquiring Wyeth in a cash-and-stock transaction to
>       create the world's premier biopharmaceutical company. The acquisition remains
>       subject to customary closing conditions, including approval by the stockholders
>       of Wyeth, and regulatory approval in certain jurisdictions. Pfizer and Wyeth
>       continue to expect the transaction to close at the end of the third quarter
>       or during the fourth quarter of 2009.
>     ABOUT PFIZER
>       Pfizer Inc, founded in 1849, is dedicated to better health and greater access
>       to health care for people and their valued animals. Every day, more than
>       80,000 colleagues in more than 90 countries work to discover, develop, manufacture
>       and deliver quality, safe and effective prescription medicines to patients.
>     ABOUT WYETH
>       Wyeth is one of the world's largest research-driven pharmaceutical and health
>       care products companies. It is a leader in the discovery, development, manufacturing
>       and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals
>       and non-prescription medicines that improve the quality of life for people
>       worldwide. Wyeth's major divisions include Wyeth Pharmaceuticals, Wyeth
>       Consumer Healthcare and Fort Dodge Animal Health.
>     Forward Looking Statements 
>       This press release includes "forward-looking statements" within
>       the meaning of the safe harbor provisions of the United States Private Securities
>       Litigation Reform Act of 1995. Such statements may include, but are not
>       limited to, statements about the benefits of the proposed merger between
>       Pfizer and Wyeth, including future financial and operating results, the
>       combined company's plans, objectives, expectations and intentions and other
>       statements that are not historical facts. Such statements are based upon
>       the current beliefs and expectations of Pfizer's and Wyeth's management
>       and are subject to significant risks and uncertainties. Actual results may
>       differ from those set forth in the forward-looking statements. Neither Pfizer
>       nor Wyeth undertake any obligation to update publicly or revise any forward-looking
>       statements. The following factors, among others, could cause actual results
>       to differ from those set forth in the forward-looking statements: the possibility
>       that the expected synergies from the proposed merger of Pfizer and Wyeth
>       will not be realized, or will not be realized within the expected time period,
>       due to, among other things, the impact of pharmaceutical industry regulation
>       and pending legislation that could affect the pharmaceutical industry; the
>       ability to obtain governmental and self-regulatory organization approvals
>       of the merger on the proposed terms and schedule; the failure of Wyeth stockholders
>       to approve the merger; the risk that the businesses will not be integrated
>       successfully; disruption from the merger making it more difficult to maintain
>       business and operational relationships; the possibility that the merger
>       does not close, including, but not limited to, due to the failure to satisfy
>       the closing conditions; Pfizer's and Wyeth's ability to accurately predict
>       future market conditions; dependence on the effectiveness of Pfizer's and
>       Wyeth's patents and other protections for innovative products; the risk
>       of new and changing regulation and health policies in the US and internationally
>       and the exposure to litigation and/or regulatory actions. Additional factors
>       that could cause results to differ materially from those described in the
>       forward-looking statements can be found in Pfizer's 2008 Annual Report on
>       Form 10-K filed with the Securities and Exchange Commission (the "SEC")
>       on February 27, 2009, Wyeth's 2008 Annual Report on Form 10-K filed with
>       the SEC on February 27, 2009, including in the "Risk Factors"
>       section of each of these filings, and each company's other filings with
>       the SEC available at the SEC's Internet site (http://www.sec.gov).
>     Additional Information
>       In connection with the proposed acquisition of Wyeth, Pfizer filed with
>       the SEC a Registration Statement on Form S-4 on March 27, 2009 that includes
>       a preliminary proxy statement of Wyeth that also constitutes a prospectus
>       of Pfizer. At the appropriate time, Wyeth will mail the final proxy statement/prospectus
>       to its stockholders. Pfizer and Wyeth urge investors and security holders
>       to read the proxy statement/prospectus regarding the proposed acquisition
>       because it contains important information. You may obtain copies of all
>       documents filed with the SEC regarding this transaction, free of charge,
>       at the SEC's website (www.sec.gov). You may also obtain these documents,
>       free of charge, from Pfizer's website, www.pfizer.com, under the tab "Investors"
>       and then under the tab "SEC Filings". You may also obtain these
>       documents, free of charge, from Wyeth's website, www.wyeth.com, under the
>       heading "Investor Relations" and then under the tab "Financial
>       Reports/SEC Filings". Pfizer, Wyeth and their respective directors,
>       executive officers and certain other members of management and employees
>       may be soliciting proxies from Wyeth stockholders in favor of the proposed
>       acquisition. Information regarding the persons who may, under the rules
>       of the SEC, be deemed participants in the solicitation of the Wyeth stockholders
>       in connection with the proposed acquisition is set forth in the proxy statement/prospectus.
>       You can find information about Pfizer's executive officers and directors
>       in its definitive proxy statement filed with the SEC on March 13, 2009.
>       You can find information about Wyeth's executive officers and directors
>       in its preliminary proxy statement filed with the SEC on March 27, 2009
>       by Pfizer on Form S-4.
>     
>     # # # # #